Top Markets
#1 Akedo Akedo +61.65%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +50.50%
#4 Cross Cross +46.58%
#5 Black Phoenix Black Phoenix +34.22%
#6 Velvet Velvet +31.90%
#7 OVERTAKE OVERTAKE +27.47%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +16.31%
#9 Not in Employment, Education, or Training Not in Employment, Education, or Training +14.54%
#10 Movement Movement +13.62%
Coin of the day
Akedo Akedo
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
HVIVO plc HVIVO plc

HVIVO plc

HVO
Rang in Aktien #39181
hVIVO plc (HVO) operates as a premier full-service Contract Research... hVIVO plc (HVO) operates as a premier full-service Contract Research Organisation (CRO) focused on early-phase clinical development, globally recognized as the leader in human challenge trials. The company provides a complete spectrum of clinical development services to a wide-ranging and growing client base, which includes seven of the world's ten largest biopharmaceutical companies. A key specialisation for hVIVO is orchestrating human challenge trials across numerous infectious and respiratory diseases, utilising its advanced, London-based quarantine facility, the largest of its kind globally. Additionally, the company offers extensive virology and immunology laboratory services through its hLAB division. Through its German subsidiary, CRS, hVIVO manages a 120-bed capacity across sites in Mannheim and Kiel, delivering early-phase clinical trial expertise, including first-in-human and proof-of-concept studies. Its other subsidiary, Venn Life Sciences, contributes to the biopharma sector by providing specialist early drug development consulting and biometry services. The Group collectively offers integrated drug development solutions, covering stages from preclinical research up to Phase II trials, supported by patient recruitment via FluCamp. Moreover, its five clinical sites facilitate outpatient Phase II and III trials, ensuring a streamlined and effective transition from drug discovery to late-stage development.
Aktienkurs
$0.08912595
Marktkapitalisierung
$613.54K
Veränderung (1 Tag)
-2.24%
Veränderung (1 Jahr)
-35.73%
Land
GB
Handel HVIVO plc (HVO)

Kategorie

Healthcare
Kursverlauf für HVIVO plc (HVO)
Höchster Schlusskurs: $0.09 am 2026-08-01

Niedrigster Schlusskurs: $0.55 am 2012-12-01
Kursverlauf der Aktie von HVIVO plc von 2012 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2026 (TTM) 25.50%
2025 -69.91%
2024 -3.74%
2023 98.73%
2022 -51.22%
2021 -10.78%
2020 335.59%
2019 194.91%
2018 -84.83%
2017 -45.35%
2016 -9.46%
2015 14.83%
2014 -31.84%
2013 -23.92%
2012 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $507.69 30.08%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $848.55 30.06%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $731.69 7.13%
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 $1.07K -6.40%
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $251.82 11.25%
BE